Bionano Genomics, Inc. (BNGO) officer discloses 5,000-share option
Rhea-AI Filing Summary
Bionano Genomics, Inc. reports that Principal Accounting Officer Mark Adamchak holds a stock option covering 5,000.0000 shares of common stock at an exercise price of 1.1200 per share, expiring on 2036-08-02. The option vests 50% on each of the first and second anniversaries of the vesting commencement date, subject to his Continuous Service under the company’s 2018 Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Adamchak Mark
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,000 shares (Direct)
Footnotes (1)
- F1. The shares subject to the option vest 50% of the total on each of the first and second anniversaries of the vesting commencement date, in each case subject to the Reporting Person's Continuous Service (as defined in the Company's 2018 Plan) through each applicable vesting date.
Key Figures
Underlying shares: 5000.0000 shares
Exercise price: 1.1200
Expiration date: 2036-08-02
+1 more
4 metrics
Underlying shares
5000.0000 shares
Shares of common stock underlying reported Stock Option (Right to Buy)
Exercise price
1.1200
Exercise price per share of the reported stock option
Expiration date
2036-08-02
Expiration date of the reported stock option
Vesting schedule
50% / 50%
Option vests 50% on each of the first and second anniversaries of vesting commencement date
Key Terms
Stock Option (Right to Buy), Continuous Service, vesting commencement date, 2018 Plan
4 terms
Stock Option (Right to Buy) financial
"security title "Stock Option (Right to Buy)" for derivative holding"
Continuous Service financial
"subject to the Reporting Person's Continuous Service under the Company's 2018 Plan"
vesting commencement date financial
"first and second anniversaries of the vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
2018 Plan financial
"as defined in the Company's 2018 Plan through each applicable vesting date"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider role does Mark Adamchak hold at Bionano Genomics (BNGO)?
Mark Adamchak is reported as the Principal Accounting Officer of Bionano Genomics, Inc. This officer role places him in charge of key accounting functions and is the basis for his requirement to file a Form 3 disclosing his equity holdings.
What stock option holding did Mark Adamchak report in BNGO’s Form 3?
He reported a Stock Option (Right to Buy) tied to 5,000.0000 shares of Bionano Genomics common stock. The option has an exercise price of 1.1200 and an expiration date of 2036-08-02, and is held directly.
How do Mark Adamchak’s BNGO stock options vest?
The reported option vests 50% of the total shares on each of the first and second anniversaries of the vesting commencement date. Each vesting installment is conditioned on his Continuous Service under Bionano Genomics’ 2018 Plan through the applicable vesting date.
Are Mark Adamchak’s BNGO options held directly or indirectly?
The filing characterizes the option as held directly by Mark Adamchak. The ownership code is listed as “D” for direct ownership, and there is no indication of an intermediary entity such as a trust or partnership for this particular derivative holding.
What is the underlying security for Mark Adamchak’s BNGO stock option?
The underlying security for the reported derivative is Common Stock of Bionano Genomics, Inc. The option relates to 5,000.0000 underlying shares, meaning that, upon exercise and subject to vesting, it could convert into that number of common shares.